Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

Ítems similars

• Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
  per: Huang, Fenglei, et al.
  Publicat: (2008)
• Future of nonnucleoside reverse transcriptase inhibitors
  per: Sluis-Cremer, Nicolas
  Publicat: (2018)
• Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults
  per: Kityo, C., et al.
  Publicat: (2010)
• Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects
  per: Zhou, Xiao-Jian, et al.
  Publicat: (2009)
• Mechanisms of inhibition of HIV replication by nonnucleoside reverse transcriptase inhibitors
  per: Sluis-Cremer, Nicolas, et al.
  Publicat: (2008)